2CV Stock Chart & Stats
€2.56
€0.14(5.83%)
At close: 4:00 PM EDT
€2.56
€0.14(5.83%)
Day’s Range― - ―
52-Week Range€2.14 - €2.92
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€5.61B
Enterprise Value€5.45B
Total Cash (Recent Filing)€99.51M
Total Debt (Recent Filing)€1.75B
Price to Earnings (P/E)51.9
Beta0.79
Next Earnings
Feb 23, 2027EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,912,231,000
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio-7.33
Price to Book (P/B)4.36
Price to Sales (P/S)2.66
P/FCF Ratio19.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.72Price Target Upside45.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.24
Revenue Forecast (FY)€3.05B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelConvaTec’s portfolio is built around disposable and replenished medical products used by chronic-care patients and healthcare providers. This recurring demand supports revenue visibility, reduces reliance on one-time purchases, and provides a durable foundation for growth across home-care and clinical settings.
Revenue And Margin ImprovementSteady multi-year revenue growth alongside materially higher operating margins indicates improving scale and cost control. If maintained, this combination can strengthen earnings power, support investment in new products and capacity, and improve resilience across the company’s medical consumables portfolio.
Infusion Care GrowthInfusion Care is showing strong demand in diabetes and particularly rapid growth outside diabetes, including Parkinson’s infusion sets. Continued momentum in this category, supported by capacity investment and consumable replacement, offers a durable growth engine beyond the more mature parts of the portfolio.
Bears Say
Higher LeverageThe increase in debt relative to equity reduces financial flexibility and makes results more sensitive to earnings pressure or changes in financing conditions. Higher leverage can also constrain future capital allocation, particularly while ConvaTec is funding growth investment and shareholder distributions.
Moderate Cash ConversionAlthough operating and free cash flow remain positive, conversion below reported earnings indicates that accounting profit is not fully translating into distributable cash. Persistent weaker conversion could limit internally funded investment, reduce flexibility for capital returns, and make earnings quality less robust.
InnovaMatrix SetbackThe sharp sales decline and impairment show that InnovaMatrix has materially underperformed expectations and created a lasting drag on the portfolio. Management now expects only $5m–$10m of 2026 revenue, reducing the product’s contribution while highlighting execution risk in newer offerings.
ConvaTec News
2CV FAQ
What was ConvaTec’s price range in the past 12 months?
ConvaTec lowest stock price was €2.14 and its highest was €2.92 in the past 12 months.
What is ConvaTec’s market cap?
ConvaTec’s market cap is €5.61B.
When is ConvaTec’s upcoming earnings report date?
ConvaTec’s upcoming earnings report date is Feb 23, 2027 which is in 120 days.
How were ConvaTec’s earnings last quarter?
ConvaTec released its earnings results on Aug 04, 2026. The company reported €0.076 earnings per share for the quarter, beating the consensus estimate of €0.074 by €0.002.
Is ConvaTec overvalued?
According to Wall Street analysts ConvaTec’s price is currently Undervalued.
Does ConvaTec pay dividends?
ConvaTec does not currently pay dividends.
What is ConvaTec’s EPS estimate?
ConvaTec’s EPS estimate is 0.1.
How many shares outstanding does ConvaTec have?
ConvaTec has 1,912,231,000 shares outstanding.
What happened to ConvaTec’s price movement after its last earnings report?
ConvaTec reported an EPS of €0.076 in its last earnings report, beating expectations of €0.074. Following the earnings report the stock price went up 7.977%.
Which hedge fund is a major shareholder of ConvaTec?
Currently, no hedge funds are holding shares in DE:2CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ConvaTec Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.72 (45.23% Upside)
€3.72 (45.23% Upside)
Insider Transactions
Bought Shares
Worth €201.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.30%
12-Months-Change
Fundamentals
Return on Equity
8.40%
Trailing 12-Months
Asset Growth
3.64%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
2CV Stock 12 Month Forecast
Average Price Target
€3.72
▲(45.23% Upside)








